$24.46
0.843.56%
Last update: Dec 15, 2:56 PM
Comments
Loading...
Catalyst Pharmaceuticals Stock Guidance
CPRXNASDAQ
Catalyst Pharmaceuticals Stock Guidance | NASDAQ:CPRX | Benzinga
Catalyst Pharmaceuticals issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/05/2025 | CPRX | Catalyst Pharmaceuticals | FY | 2025 | — | — | — | $565.00M | $585.00M | $561.83M | Get Alert |
| 08/06/2025 | CPRX | Catalyst Pharmaceuticals | FY | 2025 | — | — | — | $545.00M | $565.00M | $560.40M | Get Alert |
| 05/07/2025 | CPRX | Catalyst Pharmaceuticals | FY | 2025 | — | — | — | $545.00M | $565.00M | $557.23M | Get Alert |
| 02/26/2025 | CPRX | Catalyst Pharmaceuticals | FY | 2025 | — | — | — | $545.00M | $565.00M | $558.08M | Get Alert |
| 11/06/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $475.00M | $485.00M | $473.67M | Get Alert |
| 08/07/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $455.00M | $475.00M | $462.43M | Get Alert |
| 05/08/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $455.00M | $475.00M | $460.53M | Get Alert |
| 02/28/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $455.00M | $475.00M | $463.19M | Get Alert |
| 11/08/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $390.00M | $395.00M | $389.14M | Get Alert |
| 08/09/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $380.00M | $390.00M | $380.21M | Get Alert |
| 06/01/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $380.85M | Get Alert |
| 05/10/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $381.54M | Get Alert |
| 03/15/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $380.33M | Get Alert |
| 02/07/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $214.00M | $214.00M | $210.36M | Get Alert |
| 02/07/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $337.63M | Get Alert |
| 02/07/2023 | CPRX | Catalyst Pharmaceuticals | Q4 | 2022 | — | — | — | $61.00M | $61.00M | $56.84M | Get Alert |
| 11/09/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $205.00M | $210.00M | $205.03M | Get Alert |
| 08/09/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $200.85M | Get Alert |
| 05/10/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $199.99M | Get Alert |
| 03/16/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $198.45M | Get Alert |
| 02/07/2022 | CPRX | Catalyst Pharmaceuticals | Q4 | 2021 | — | — | — | $38.00M | $38.00M | $36.85M | Get Alert |
| 02/07/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2021 | — | — | — | $141.00M | $141.00M | $138.30M | Get Alert |
| 02/07/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $163.53M | Get Alert |
FAQ
Q
What is the most recent guidance for Catalyst Pharmaceuticals (CPRX)?
A
There have been no specific sales or earnings guidance reported for Catalyst Pharmaceuticals in recent months.
Browse guidance and forecast on all stocks.
People Also Watch
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved